Idursulfase
From Infogalactic: the planetary knowledge core
| Clinical data | |
|---|---|
| AHFS/Drugs.com | monograph |
| Identifiers | |
| CAS Number | 50936-59-9  |
| ATC code | A16AB09 (WHO) |
| DrugBank | DB01271 |
| UNII | 5W8JGG2651 |
| KEGG | D04499 |
| ChEMBL | CHEMBL1201826  |
| (what is this?) (verify) |
|
Idursulfase (brand name Elaprase), manufactured by Shire, is a drug used to treat Hunter syndrome (also called MPS-II).[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[2][3][4]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
- ↑ [1], Barbara Kollmeyer, Marketwatch, Fed. 3, 2016
External links
- idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
